Benralizumab (Fasenra®) is indicated as add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||15/01/2018|
|Rapid review completed||14/02/2018|
|Rapid Review outcome||Full pharamcoeconomic assessment recommended at the submitted price|
The HSE has approved reimbursement following confidential price negotiations; April 2019